The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
treatments for type 2 diabetes, lowering glycated haemoglobin (HbA 1c) and weight, but are …

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

Oral administration provides a simple and non-invasive approach for drug delivery.
However, due to poor absorption and swift enzymatic degradation in the gastrointestinal …

The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic
levels, however, challenges such as rapid renal clearance, degradation or non-specific …

Oral administration is perhaps the most commonly used and acceptable route for drug
delivery to patients, mainly due to its non-invasiveness, simplicity, and versatility …

It is increasingly apparent that not only is a cure for the current worldwide diabetes epidemic
required, but also for its major complications, affecting both small and large blood vessels …

Aims To determine the effect of the glucagon‐like peptide‐1 analogue liraglutide on left
ventricular function in chronic heart failure patients with and without type 2 diabetes …